Company / Interest Expense
United Therapeutics Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$59.3M
FY2023
5-year range
$18.6M / $59.3M
FY2019-FY2023
Trend
+83.0%
vs FY2022
Sector context
#12 of 44
Health Care
What the data says
At $59M, United Therapeutics's interest expense ranks #33 of 44 in the Health Care sector. Increased from $19M to $59M over the past 2 years.
Based on SEC 10-K filings.
$59M in FY2023 with a 5-year CAGR of +33.7%.
Increased from $19M to $59M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +36.1%
- 5-Year CAGR
- +33.7%
- 10-Year CAGR
- -
Sector benchmark
#33 of 44 in Health CareTop 73% of 44This company $59.3M Sector average $291.0M
▼
-79.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +33.7%, indicating consistent growth.
- In FY2023, interest expense increased 83.0% year-over-year.
- Ranks #12 out of 44 companies in the Health Care sector.
- Lowest interest expense in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $59.3M | +83.0% |
| FY2022 | $32.4M | +74.2% |
| FY2021 | $18.6M | -20.9% |
| FY2020 | $23.5M | -46.8% |
| FY2019 | $44.2M | +218.0% |
| FY2018 | $13.9M | +195.7% |
| FY2017 | $4.7M | +20.5% |
| FY2016 | $3.9M | -17.0% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026